Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







26.05.2019

Valneva: Valneva SE, a French/Austrian biotech company developing and commercializing vaccines for infectious diseases with major unmet medical needs, today announced further positive Phase 1 results for its chikungunya vaccine candidate, VLA1553. The results showed an excellent immunogenicity profile in all vaccinated dose groups after a single vaccination with a 100% Seroconversion1 achieved at Day 14 after a single vaccination in all dose groups and fully sustained at 100% at Month 6. The objectives of VLA1553-101 Phase 1 study were to assess the overall safety and immunogenicity profile after a single vaccination across three dose levels. Today ?s analysis (Part B) of the ongoing study includes the overall safety and immunogenicity results up to Month 7, unblinded on a group level and including first results from the “intrinsic human viral challenge”.  Valneva is committed to advancing its chikungunya vaccine candidate as quickly as possible and expects to be in a position to announce a plan, agreed with regulators, to licensure for its FDA fast tracked candidate VLA1553 at its planned R&D investor day, July 9th in New York.
Valneva: weekly performance: -0.60%

Vienna Insurance Group: Vienna Insurance Group (VIG) continued to grow in the first quarter of 2019. Total premium volume has reached EUR 2.9 billion in the first three months of 2019. This implies a 2.9% year-on-year increase. Health insurance recorded the largest premium growth of around 10%. Single-premium life insurance, which only reported a small quarter-on-quarter decrease of around 2% in the first quarter, now shows the improvement that was expected after the large decreases that were intentionally recorded in the past. The markets in Bulgaria, the Baltic states, Hungary and Poland contributed exceptional premium increases in the 1st quarter of 2019. Profit (before taxes) amounts to Euro 127.5 mn. This implies an 8.7% year-on-year increase. The Austria, Slovakia and Poland segments made particularly large contributions to the increase in profit. Profit (after taxes and non-controlling interests) rose by 10.5% to Euro 83.5 mn. Elisabeth Stadler, CEO of Vienna Insurance Group, commented: "We can look back on a successful first quarter of 2019, with results that are clearly in line with our expectations. Therefore, we maintain our targets to achieve a premium volume of EUR 9.9 billion and profit (before taxes) of EUR 500 to 520 million in 2019”.
VIG: weekly performance: -5.79%

FACC: Aerospace supplier FACC AG was again able to benefit from the global market environment of the aerospace industry and achieved solid growth in the 2018/19 financial year. In the 2018/19 financial year, the FACC Group generated revenues rose by 4.5 % to Euro 781.6 mn. The main drivers of product sales in the 2018/19 financial year were the programs for the Airbus A320 family, Airbus A350 XWB, Boeing 787 as well as the Bombardier and Embraer Business Jets and the associated engines. The first significant series revenues were generated also with the aircraft manufacturer COMAC in the financial year 2018/19. Operating earnings before interest and taxes (EBIT) increased significantly in the past financial year from Euro 44.9 mn to Euro 55.0 mn. CEO Robert Machtlinger: "Over the past 30 years, we have consistently worked on the technological development of the company and have risen from a start-up to a world-class group. We are proud of the past 30 years, but we will not pause for a moment. On the contrary, we are going into the next 30 years with full vigor".
FACC: weekly performance: -8.19%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/05/2019)


 

Bildnachweis

1. Valneva - Valneva hat eben seinen 5. Jahrestag gefeiert und wir gehen davon aus, in diesem Jahr einen Produktumsatz von € 100 Mio. zu erreichen. Unser Impfstoffkandidat gegen Lyme Borreliose, derzeit das einzige klinische Entwicklungsprogramm seiner Art, steht kurz vor dem Eintritt in eine Phase 2-Studie und mehrere US-Healthcare-Fonds unterstützen nun unsere Wachstumsstrategie. Sowohl auf der kom



Aktien auf dem Radar: Andritz , EVN , OMV , Semperit , Marinomed Biotech , Addiko Bank , Frequentis , CA Immo , DO&CO , Rosenbauer , Uniqa , Amag , S Immo , voestalpine , Gurktaler AG Stamm , Gurktaler AG VZ , Management Trust Holding , SW Umwelttechnik , Fabasoft .


Random Partner

Palfinger
Palfinger zählt zu den international führenden Herstellern innovativer Hebe-Lösungen, die auf Nutzfahrzeugen und im maritimen Bereich zum Einsatz kommen. Der Konzern verfügt über 5.000 Vertriebs- und Servicestützpunkte in über 130 Ländern in Europa, Nord- und Südamerika sowie Asien.

>> Besuchen Sie 52 weitere Partner auf boerse-social.com/partner